Cholecystokinin Octapeptide Ammonium: Mechanisms, Benchmarks, and Best Practices

Executive Summary: Cholecystokinin octapeptide ammonium (CCK-8 ammonium, SKU C8717) is a chemically defined, sulfated brain–gut peptide that selectively activates CCK1R and CCK2R receptors at nanomolar to micromolar concentrations [APExBIO]. Its biological effects—ranging from inhibition of apoptosis to modulation of anxiety-like behaviors and immune responses—are context-dependent and concentration-specific (Han et al., 1986). The peptide's sulfation state is essential for its activity, as desulfated forms lose key physiological functions. CCK-8 ammonium is a preferred agonist in both in vitro and in vivo studies due to its high solubility in DMSO and stability when stored at -20°C under nitrogen [Mechanisms & Benchmarks]. This article details the mechanistic, empirical, and methodological landscape for optimal use and interpretation.

Biological Rationale

Cholecystokinin octapeptide ammonium (CCK-8 ammonium) is the ammonium salt of the sulfated octapeptide form of cholecystokinin (CCK-8s), a peptide found in both the central nervous system and gastrointestinal tract [APExBIO]. In the CNS, CCK-8 modulates neuronal activity, anxiety, and pain response via G protein–coupled receptors CCK1R and CCK2R (Han et al., 1986). In the periphery, it regulates digestive and cardiac functions, notably inducing gallbladder contraction and promoting atrial natriuretic peptide (ANP) secretion. The peptide’s pleiotropic actions are concentration- and tissue-specific, with critical dependence on the sulfation of the tyrosine-7 residue for high-affinity receptor binding and downstream effects [Mechanisms, Evidence & Workflows].

Mechanism of Action of Cholecystokinin octapeptide ammonium

CCK-8 ammonium acts as a selective agonist for CCK1R and CCK2R receptors. Upon binding, it triggers multiple intracellular signaling cascades:

• β-arrestin 2 recruitment and receptor internalization
• Activation of p38 MAPK and Akt pathways, leading to altered cell survival and apoptosis profiles
• Induction of NOX4 and PGC-1α signaling, impacting oxidative metabolism
• Modulation of PPARα and PPARγ transcriptional activity

In neuronal cells, CCK-8 ammonium can inhibit apoptosis at 0.01–1 μmol/L in vitro, and modulate anxiety-like behaviors at nanogram doses in vivo (Han et al., 1986). The peptide also regulates endorphin release by interacting with μ-opioid receptors, antagonizing opioid-induced analgesia but not affecting serotonin or norepinephrine pathways. Sulfation is a prerequisite for these activities; the desulfated analog is inactive in most physiological contexts [Neurobiological Mechanisms].

Evidence & Benchmarks

• CCK-8 ammonium antagonizes morphine- and electroacupuncture-induced analgesia at 0.25–4 ng (i.c.v./i.th.) in rats, with effect onset within 15 minutes and lasting ≥4 hours (Han et al., 1986).
• Sulfated CCK-8 induces anxiety-like behaviors in zebrafish and rodents, whereas its desulfated form does not (Mechanisms, Evidence & Workflows).
• CCK-8 ammonium inhibits apoptosis in neuronal and immune cells at 0.01–1 μmol/L in vitro under serum-deprivation stress (Mechanisms & Benchmarks).
• Promotion of ANP secretion in atrial cells is strictly dependent on the sulfated state (APExBIO).
• CCK-8 does not affect serotonin- or norepinephrine-induced analgesia in rats (Han et al., 1986, DOI).
• CCK-8 antiserum reverses tolerance to morphine and electroacupuncture analgesia, confirming endogenous CCK-8’s anti-opioid role (Han et al., 1986, DOI).
• In vitro and in vivo workflows show high reproducibility using APExBIO’s CCK-8 ammonium (C8717), with optimal solubility in DMSO and recommended storage at -20°C under nitrogen (Solving Experimental Challenges).

Applications, Limits & Misconceptions

Cholecystokinin octapeptide ammonium is used in diverse research areas:

• Neuroscience: Model anxiety-like behaviors and study opioid tolerance mechanisms
• Immunology: Assess T-cell and macrophage modulation under CCK-8 exposure
• Cardiovascular physiology: Probe ANP secretion and cardiac signaling
• Cell biology: Investigate apoptosis and caspase signaling via CCK-8/CCK1R/CCK2R axis

Find a comprehensive application overview in "Applied Workflows & Troubleshooting", which this article extends by emphasizing new receptor and signaling benchmarks.

Common Pitfalls or Misconceptions

• Desulfated CCK-8 is inactive: Only sulfated CCK-8 induces ANP secretion and anti-analgesic effects.
• Opioid-specific antagonism: CCK-8 antagonizes only opioid-induced analgesia, not serotonin or norepinephrine pathways.
• Concentration dependence: Effects are highly dose-dependent; sub- or supraphysiological concentrations yield non-physiological responses.
• Solution stability: CCK-8 solutions are not suitable for long-term storage; fresh preparation is essential for reproducibility.
• Species/route differences: In vivo dosing varies by species and administration route; extrapolation requires empirical validation.

Workflow Integration & Parameters

For in vitro studies, dissolve CCK-8 ammonium in DMSO to 1–10 mmol/L stock; working concentrations are typically 0.01–1 μmol/L. Store lyophilized peptide at -20°C, sealed, dry, and under nitrogen to prevent oxidation [Product Page]. For animal studies, intrathecal or intracerebroventricular doses of 0.25–4 ng per rat are standard in analgesia models (Han et al., 1986). Avoid repeated freeze-thaw cycles. For further troubleshooting, see "Solving Experimental Challenges", which this article updates with new handling and storage insights.

Conclusion & Outlook

Cholecystokinin octapeptide ammonium (CCK-8 ammonium, C8717, APExBIO) provides a high-purity, research-grade tool to dissect CCK receptor–mediated signaling in neuroscience, immunology, and cell biology. Its efficacy hinges on sulfation status, concentration, and context. Future advances will clarify the peptide’s roles in translational models of pain, anxiety, and immune modulation. For up-to-date mechanistic and workflow data, this article augments prior content such as "Mechanisms & Benchmarks" by mapping new evidence on receptor specificity and signaling pathways.